BerGenBio reports Phase II data for AXL inhibitor

BerGenBio ASA (OSE:BGBIO) reported data from its Phase II trials of bemcentinib (BGB324) to treat acute myelogenous leukemia (AML) and other cancers. Data were presented at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco.

Among 35 evaluable patients with relapsed or refractory AML or myelodysplastic syndrome (MDS) in the Phase II portion of the Phase Ib/II BGBC003 trial, bemcentinib as monotherapy led to two complete responses with incomplete recovery of peripheral counts (CRi) and five partial responses, plus eight cases of stable disease for more than four months. The open-label, international trial is enrolling up to 75 patients and is also evaluating bemcentinib plus cytarabine and decitabine. The primary endpoint is maximum tolerated dose (MTD)...